Acute Pain - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 189 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acute Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2014', provides an overview of the Acute Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Pain Overview 9
Therapeutics Development 10
Pipeline Products for Acute Pain - Overview 10
Pipeline Products for Acute Pain - Comparative Analysis 11
Acute Pain - Therapeutics under Development by Companies 12
Acute Pain - Therapeutics under Investigation by Universities/Institutes 16
Acute Pain - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Acute Pain - Products under Development by Companies 20
Acute Pain - Products under Investigation by Universities/Institutes 24
Acute Pain - Companies Involved in Therapeutics Development 25
Nektar Therapeutics 25
Santen Pharmaceutical Co., Ltd. 26
Pacira Pharmaceuticals, Inc. 27
AcelRx Pharmaceuticals, Inc. 28
Laboratorios Del Dr. Esteve S.A. 29
Glenmark Pharmaceuticals Ltd. 30
Kowa Company, Ltd. 31
Pfizer Inc. 32
Sigma-Tau S.p.A. 33
A. Menarini Industrie Farmaceutiche Riunite Srl 34
Anavex Life Sciences Corp. 35
Nuvo Research Inc. 36
Paladin Labs Inc. 37
Yungjin Pharm Ind. Co., Ltd. 38
INSYS Therapeutics, Inc. 39
Grunenthal GmbH 40
AngioChem Inc. 41
Charleston Laboratories, Inc. 42
Trevena, Inc. 43
Syntrix Biosystems, Inc. 44
Kineta, Inc. 45
Rottapharm SpA 46
QRxPharma Limited 47
Cara Therapeutics, Inc. 48
Encore Therapeutics Inc. 49
KemPharm, Inc. 50
Cytogel Pharma, LLC 51
MEDRx Co., Ltd. 52
Thar Pharmaceuticals, Inc. 53
Hanmi Pharmaceuticals, Co. Ltd. 54
Adynxx, Inc. 55
AnaBios Corporation 56
Nanomerics Ltd 57
ChironWells GmbH 58
Mallinckrodt plc 59
Acute Pain - Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Target 62
Assessment by Mechanism of Action 66
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
ARX-01 - Drug Profile 74
(hydrocodone + acetaminophen) ER - Drug Profile 77
(morphine + oxycodone) IR - Drug Profile 78
tapentadol hydrochloride - Drug Profile 80
(acetaminophen + tramadol hydrochloride) - Drug Profile 81
(morphine + oxycodone) IR - Drug Profile 83
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 85
(etodolac + lidocaine ) - Drug Profile 86
CL-108 - Drug Profile 88
K-103IP - Drug Profile 89
(acetaminophen + tramadol hydrochloride) SR - Drug Profile 90
CR-4056 - Drug Profile 91
(morphine + oxycodone) - Drug Profile 92
(benzhydrocodone hydrochloride + acetaminophen) - Drug Profile 94
CR-845 - Drug Profile 95
(lidocaine + tetracaine) - Drug Profile 97
ARX-04 - Drug Profile 99
ketamine hydrochloride - Drug Profile 100
RQ-00317076 - Drug Profile 101
(aceclofenac + eperisone) - Drug Profile 102
(celecoxib + tramadol hydrochloride) - Drug Profile 103
E-52862 - Drug Profile 105
AYX-1 - Drug Profile 106
CR-845 - Drug Profile 107
Cyt-1010 - Drug Profile 109
PF-06273340 - Drug Profile 111
grapiprant - Drug Profile 112
HS-731 - Drug Profile 114
GRC-27864 - Drug Profile 115
TRV-734 - Drug Profile 116
lidocaine - Drug Profile 117
ANAVEX-1037 - Drug Profile 118
ANAVEX-1519 - Drug Profile 119
ANG-2002 - Drug Profile 120
Small Molecules to Agonize Kappa Opioid Receptor for CNS Disorder - Drug Profile 121
RQ-00000008 - Drug Profile 122
DepoNSAID ER - Drug Profile 123
ANAVEX-1066 - Drug Profile 124
NKTR-192 - Drug Profile 125
T-109 - Drug Profile 126
conolidine - Drug Profile 127
buprenorphine hydrochloride ER - Drug Profile 128
FY-101C - Drug Profile 129
grapiprant - Drug Profile 130
ANAVEX-1005 - Drug Profile 132
HS-731 - Drug Profile 133
Small Molecules to Block Nav 1.7 for Pain - Drug Profile 134
ST-4070 - Drug Profile 135
Prostatic Acid Phosphatase - Drug Profile 136
VPX-595 - Drug Profile 137
U-2902 - Drug Profile 138
CLHL - Drug Profile 139
CLH-5 - Drug Profile 140
CLH-10 - Drug Profile 141
Omnitram - Drug Profile 142
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile 143
SA-14867 - Drug Profile 144
NM-0127 - Drug Profile 145
ET-1 - Drug Profile 146
RO-656570 - Drug Profile 147
ibuprofen - Drug Profile 148
buprenorphine hydrochloride - Drug Profile 149
NKTR-196 - Drug Profile 150
X-0002 - Drug Profile 151
Acute Pain - Recent Pipeline Updates 153
Acute Pain - Dormant Projects 177
Acute Pain - Discontinued Products 179
Acute Pain - Product Development Milestones 180
Featured News & Press Releases 180
Appendix 184
Methodology 184
Coverage 184
Secondary Research 184
Primary Research 184
Expert Panel Validation 184
Contact Us 185
Disclaimer 185

List of Tables
Number of Products under Development for Acute Pain, H2 2014 14
Number of Products under Development for Acute Pain - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Late Stage Development, H2 2014 21
Comparative Analysis by Clinical Stage Development, H2 2014 22
Comparative Analysis by Early Stage Development, H2 2014 23
Products under Development by Companies, H2 2014 24
Products under Development by Companies, H2 2014 (Contd..1) 25
Products under Development by Companies, H2 2014 (Contd..2) 26
Products under Development by Companies, H2 2014 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2014 28
Acute Pain - Pipeline by Nektar Therapeutics, H2 2014 29
Acute Pain - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 30
Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2014 31
Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2014 32
Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2014 33
Acute Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 34
Acute Pain - Pipeline by Kowa Company, Ltd., H2 2014 35
Acute Pain - Pipeline by Pfizer Inc., H2 2014 36
Acute Pain - Pipeline by Sigma-Tau S.p.A., H2 2014 37
Acute Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 38
Acute Pain - Pipeline by Anavex Life Sciences Corp., H2 2014 39
Acute Pain - Pipeline by Nuvo Research Inc., H2 2014 40
Acute Pain - Pipeline by Paladin Labs Inc., H2 2014 41
Acute Pain - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 42
Acute Pain - Pipeline by INSYS Therapeutics, Inc., H2 2014 43
Acute Pain - Pipeline by Grunenthal GmbH, H2 2014 44
Acute Pain - Pipeline by AngioChem Inc., H2 2014 45
Acute Pain - Pipeline by Charleston Laboratories, Inc., H2 2014 46
Acute Pain - Pipeline by Trevena, Inc., H2 2014 47
Acute Pain - Pipeline by Syntrix Biosystems, Inc., H2 2014 48
Acute Pain - Pipeline by Kineta, Inc., H2 2014 49
Acute Pain - Pipeline by Rottapharm SpA, H2 2014 50
Acute Pain - Pipeline by QRxPharma Limited, H2 2014 51
Acute Pain - Pipeline by Cara Therapeutics, Inc., H2 2014 52
Acute Pain - Pipeline by Encore Therapeutics Inc., H2 2014 53
Acute Pain - Pipeline by KemPharm, Inc., H2 2014 54
Acute Pain - Pipeline by Cytogel Pharma, LLC, H2 2014 55
Acute Pain - Pipeline by MEDRx Co., Ltd., H2 2014 56
Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H2 2014 57
Acute Pain - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 58
Acute Pain - Pipeline by Adynxx, Inc., H2 2014 59
Acute Pain - Pipeline by AnaBios Corporation, H2 2014 60
Acute Pain - Pipeline by Nanomerics Ltd, H2 2014 61
Acute Pain - Pipeline by ChironWells GmbH, H2 2014 62
Acute Pain - Pipeline by Mallinckrodt plc, H2 2014 63
Assessment by Monotherapy Products, H2 2014 64
Assessment by Combination Products, H2 2014 65
Number of Products by Stage and Target, H2 2014 68
Number of Products by Stage and Mechanism of Action, H2 2014 72
Number of Products by Stage and Route of Administration, H2 2014 75
Number of Products by Stage and Molecule Type, H2 2014 77
Acute Pain Therapeutics - Recent Pipeline Updates, H2 2014 157
Acute Pain - Dormant Projects, H2 2014 181
Acute Pain - Discontinued Products, H2 2014 183